Literature DB >> 19691457

Hepatitis A disease following the implementation of universal vaccination: who is at risk?

Z Mor1, S Srur, R Dagan, S Rishpon.   

Abstract

The incidence of acute hepatitis A in Israel has decreased 25 folds in less than a decade, following the introduction of a two-dose universal toddler's hepatitis A immunization in July 1999. This retrospective study describes demographic data and behavioural determinants of hepatitis A patients following the implementation of a vaccination programme. All records of hepatitis A patients reported to the Ministry of Health during the years 2003 through 2005 were reviewed, and an epidemiological investigation was conducted. During the study period, 420 hepatitis A patients were reported, representing an average annual incidence of two per 100,000 population. Case fatality rate was 0.5%. The majority of the patients were younger than 15 years of age, males and non-Jewish. The highest incidence was recorded in east Jerusalem, where vaccine coverage is relatively low. After exclusion of 165 east Jerusalem patients, 133 (52.2%) patients were available for an interview. Of those, 16 (6%) had possible occupational exposure, 37 (27.8%) travelled to endemic areas, 44 (17%) were contacts of hepatitis A cases, and 3 male patients had sex with men. No known risk determinant was identified in 33 (24.8%) patients. Four patients (3%) were previously immunized with one dose, and none had two doses. The introduction of universal toddler hepatitis A vaccination decreased morbidity. Most of the patients who were detected 4-6 years after the implementation of the vaccination programme could be classified into one of the known risk groups for hepatitis A infection or living in a partly vaccinated community.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19691457     DOI: 10.1111/j.1365-2893.2009.01176.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

1.  Hepatitis A: Epidemiology and prevention in developing countries.

Authors:  Elisabetta Franco; Cristina Meleleo; Laura Serino; Debora Sorbara; Laura Zaratti
Journal:  World J Hepatol       Date:  2012-03-27

2.  Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989-2010).

Authors:  S Ben-Shimol; R Dagan; Y Schonmann; N Givon-Lavi; N Keller; C Block; I Kassis; M Ephros; D Greenberg
Journal:  Infection       Date:  2013-03-10       Impact factor: 3.553

3.  Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan.

Authors:  Yu-Lin Lee; Kuan-Yin Lin; Chien-Yu Cheng; Chia-Wen Li; Chia-Jui Yang; Mao-Song Tsai; Hung-Jen Tang; Te-Yu Lin; Ning-Chi Wang; Yi-Chien Lee; Shih-Ping Lin; Yu-Shan Huang; Hsin-Yun Sun; Jun-Yu Zhang; Wen-Chien Ko; Shu-Hsing Cheng; Yuan-Ti Lee; Chun-Eng Liu; Chien-Ching Hung
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

4.  Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program.

Authors:  Guillermo Cervio; Julio Trentadue; Daniel D'Agostino; Carlos Luque; Mariano Giorgi; Judith Armoni; Roberto Debbag
Journal:  Hepat Med       Date:  2011-09-19

Review 5.  Live attenuated hepatitis A vaccines developed in China.

Authors:  Zhi-Yi Xu; Xuan-Yi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.